Alina IovlevaChristi L. McElhenyErin L. FowlerEric CoberErica S. HercCesar A. AriasCarol HillKeri BaumVance G. Fowler,Jr.Henry F. ChambersKerryl E. Greenwood-QuaintanceRobin PatelDavid van DuinRobert A. BonomoYohei Doi1Division of Infectious Diseases,University of Pittsburgh School of Medicine,Pittsburgh,Pennsylvania,USA2Department of Infectious Diseases,Cleveland Clinic,Cleveland,Ohio,USA3Division of Infectious Diseases,Henry Ford Hospital,Detroit,Michigan,USA4Division of Infectious Diseases,Houston Methodist Hospital,Houston,Texas,USA5Center for Infectious Diseases,Houston Methodist Research Institute,Houston,Texas,USA6Department of Medicine,Weill Cornell Medical College,New York,New York,USA7Duke Clinical Research Institute,Durham,North Carolina,USA8Division of Infectious Diseases,Duke University School of Medicine,Durham,North Carolina,USA9Division of Infectious Diseases,University of California San Francisco School of Medicine,San Francisco,California,USA10Division of Clinical Microbiology,Department of Laboratory Medicine and Pathology,Mayo Clinic,Rochester,Minnesota,USA11Division of Public Health,Infectious Diseases,and Occupational Medicine,Department of Medicine,Mayo Clinic,Rochester,Minnesota,USA12Division of Infectious Diseases University of North Carolina School of Medicine,Chapel Hill,North Carolina,USA13Department of Medicine,Division of Infectious Diseases,Case Western Reserve University School of Medicine,Cleveland,Ohio,USA14Department of Molecular Biology and Microbiology,Case Western Reserve University School of Medicine,Cleveland,Ohio,USA15Research Service,Louis Stokes Cleveland Department of Veterans Affairs Medical Center,Cleveland,Ohio,USA16CWRU-Cleveland VAMC Center for Antimicrobial Resistance and Epidemiology (Case VA CARES),Cleveland,Ohio,USA17Department of Pharmacology,Case Western Reserve University School of Medicine,Cleveland,Ohio,USA18Department of Biochemistry,Case Western Reserve University School of Medicine,Cleveland,Cleveland,Ohio,USA19Department of Proteomics and Bioinformatics,Case Western Reserve University School of Medicine,Cleveland,Ohio,USA20Clinician Scientist Investigator,Louis Stokes Cleveland Department of Veterans Affairs Medical Center,Cleveland,Ohio,USA21Departments of Microbiology and Infectious Diseases,Fujita Health University,Toyoake,Japan22Center for Innovative Antimicrobial Therapy,University of Pittsburgh School of Medicine,Pittsburgh,Pennsylvania,USA,Alessandra Carattoli

Molecular drivers of resistance to sulbactam-durlobactam in contemporary clinical isolates of Acinetobacter baumannii

Comparative Metabolomics Reveals Key Pathways Associated With the Synergistic Killing of Colistin and Sulbactam Combination Against Multidrug-Resistant Acinetobacter baumannii .

Molecular Mechanisms of Sulbactam Antibacterial Activity and Resistance Determinants in Acinetobacter Baumannii

Beyond resistance: assessing sulbactam-durlobactam's role in today's clinical landscape

Metabolic Analyses Revealed Time-Dependent Synergistic Killing by Colistin and Aztreonam Combination Against Multidrug-Resistant Acinetobacter Baumannii

In vitro activity of sulbactam-durlobactam against colistin-resistant and/or cefiderocol-non-susceptible, carbapenem-resistant Acinetobacter baumannii collected in U.S. hospitals

Hetero-antagonism of avibactam and sulbactam with cefiderocol in carbapenem-resistant Acinetobacter spp

Molecular epidemiology and mechanism of sulbactam resistance in isolates with diverse genetic background in China.

I n vitro pharmacokinetics/pharmacodynamics of the β-lactamase inhibitor, durlobactam, in combination with sulbactam against Acinetobacter baumannii-calcoaceticus complex

ETX2514 is a Broad-Spectrum Β-Lactamase Inhibitor for the Treatment of Drug-Resistant Gram-negative Bacteria Including Acinetobacter Baumannii

Acinetobacter baumannii Resistance to Sulbactam/Durlobactam: A Systematic Review

Defining optimal sulbactam regimens for treatment of Acinetobacter baumannii pneumonia and impact of blaOXA-23 on efficacy

Sulbactam-durlobactam for the treatment of acinetobacter baumannii-calcoaceticus complex

Ampicillin-sulbactam against Acinetobacter baumannii infections: pharmacokinetic/pharmacodynamic appraisal of current susceptibility breakpoints and dosing recommendations

Hetero-antagonism of avibactam and sulbactam with cefiderocol in carbapenem-resistant spp

Sulbactam–durlobactam: a β-lactam/β-lactamase inhibitor combination targeting Acinetobacter baumannii

An overview of sulbactam-durlobactam approval and implications in advancing therapeutics for hospital-acquired and ventilator-associated pneumonia by acinetobacter baumannii-calcoaceticus complex: A narrative review

Resistance, Current Treatments, and Future Innovations

Current Therapeutic Approaches for Multidrug-Resistant and Extensively Drug-Resistant Acinetobacter baumannii Infections

Pharmacodynamic Effects of Sulbactam/Meropenem/Polymyxin-B Combination Against Extremely Drug Resistant Acinetobacter baumannii Using Checkerboard Information.

Comparison of clinical outcomes for patients with monomicrobial vs polymicrobial Acinetobacter baumannii-calcoaceticus complex infections treated with sulbactam-durlobactam or colistin: A subset analysis from a phase 3 clinical trial